Dr. Lal Path labs (Large Cap - High Growth) Share Target 2026, 2027 To 2035
|
Dr. Lal PathLabs Limited |
|||
|
Price: ₹1,616.00 (0.91%) | ||
| 52 Week Low: ₹1,272.60 52 Week High: ₹1,770.00 |
|||
| Market Capital: 23,892.23 Crore (Large-cap) | |||
| Healthcare -> Diagnostics & Research | |||
Share Price HistoryLALPATHLAB FinancialsTomorrow TargetYearly TargetsDividend HistoryNo BonusNo Split
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Dr. Lal Path labs Share Price Target For 2026
- 1.1.1: Dr. Lal Path labs Share Price Target Table For 2026
- 1.1.2: Short-Term Technical Outlook
- 1.2: Dr. Lal Path labs Share Price Target For 2027
- 1.2.1: Dr. Lal Path labs Share Price Target Table For 2027
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Dr. Lal Path labs Share Price Target Chart and Table From 2026, 2027, 2028 to 2035
- 3: Dr. Lal Path labs Brief Company Overview
- 4: Dr. Lal Path labs Financial Performance
- 4.0.1: Is Dr. Lal Path labs A Good Buy For Long Term?
Dr. Lal Path labs, a Large Cap company in the Diagnostics & Research Industry has delivered 58.1% returns in 3-year showing 9.8% quarterly revenue growth with 17.1% profit margin, making it a High Growth stock.
To predict the Dr. Lal Path labs's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Dr. Lal Path labs Share Price Target For 2026
The line chart displays the monthly closing prices of Dr. Lal Path labs with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Dr. Lal Path labs shares in 2026, see the table below.
Dr. Lal Path labs Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 1822.26 (+12.76%) | Volatility: ATR T2 |
| 2026 Target 2 | 1739.75 (+7.65%) | Volatility: ATR T1 |
| 2026 Target 1 | 1688.46 (+4.48%) | Volatility: BB Upper |
| Current Price | 1616.00 | Dr. Lal Path labs's share price as of 15 Jun 2026 |
| Stop Loss 1 | 1588.05 (-1.73%) | Trend: EMA9 |
| Stop Loss 2 | 1579.99 (-2.23%) | 38.20% Weekly Fib Retrace |
| Stop Loss 3 | 1525.32 (-5.62%) | Trend: SMA50 |
Short-Term Technical Outlook
Current Technical Position: Dr. Lal Path labs is showing bullish momentum with price above both 25-day and 50-day moving averages.
Key Technical Level: The 50-day moving average at ₹1525.32 serves as the nearest technical reference point.
Historical Returns: 3-month: +20.51% | 6-month: +13.04% | 1-year: +8.45%
Dr. Lal Path labs Share Price Target For 2027
The line chart displays the monthly closing prices of Dr. Lal Path labs with a black line. The green line shows three potential target prices for 2027, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Dr. Lal Path labs shares in 2027, see the table below.
Dr. Lal Path labs Share Price Target Table For 2027
| Level | Value | Analysis |
|---|---|---|
| 2027 Target 3 | 1822.26 (+12.76%) | Volatility: ATR T2 |
| 2027 Target 2 | 1739.75 (+7.65%) | Volatility: ATR T1 |
| 2027 Target 1 | 1688.46 (+4.48%) | Volatility: BB Upper |
| Current Price | 1616.00 | Dr. Lal Path labs's share price as of 15 Jun 2026 |
| Stop Loss 1 | 1588.05 (-1.73%) | Trend: EMA9 |
| Stop Loss 2 | 1579.99 (-2.23%) | 38.20% Weekly Fib Retrace |
| Stop Loss 3 | 1525.32 (-5.62%) | Trend: SMA50 |
Long-Term Technical Outlook
52-Week Range Analysis: Dr. Lal Path labs is currently trading at 69.0% of its 52-week range (₹1272.6 - ₹1770).
Long-Term Trend Analysis: The stock is in a bearish long-term trend, trading below key long-term moving averages.
Long-Term Performance: 1-year: +8.45% | 3-year: +58.06% | 5-year: +0.84%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Dr. Lal Path labs Share Price Target Chart and Table From 2026, 2027, 2028 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹1,616.00 | ||
| 2026 | ₹1,735.56 | +7.3985148514851% | ₹1,761.59 |
| 2027 | ₹2,235.50 | +28.805688077623% | ₹2,269.03 |
| 2028 | ₹2,628.97 | +17.600984119884% | ₹2,668.40 |
| 2029 | ₹3,039.04 | +15.598123980114% | ₹3,084.63 |
| 2030 | ₹3,557.17 | +17.049133937033% | ₹3,610.53 |
| 2031 | ₹4,231.23 | +18.94933331834% | ₹4,294.70 |
| 2032 | ₹5,504.04 | +30.081323870364% | ₹5,586.60 |
| 2033 | ₹6,652.48 | +20.865400687495% | ₹6,752.27 |
| 2034 | ₹7,834.77 | +17.772169176007% | ₹7,952.29 |
| 2035 | ₹8,723.23 | +11.339962755767% | ₹8,854.08 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Dr. Lal Path labs Brief Company Overview
Dr. Lal PathLabs: Unraveling the Healthcare Industry Pioneer Established in 1949, Dr. Lal PathLabs Limited is a renowned healthcare provider that operates a vast network of laboratories across India and internationally. The company has etched its name as a leader in the...
pathology industry, offering a comprehensive range of diagnostic services that span hematology, biochemistry, microbiology, and more. Key Products and Services: Pathological investigations Diagnostic tests Training programs Dr. Lal PathLabs has garnered a strong reputation for its commitment to providing accurate and reliable diagnostic results. The company's unwavering dedication to quality is evident in its strict adherence to international standards and accreditations. Its diverse product portfolio caters to the evolving healthcare needs of both individuals and healthcare institutions alike. With a rich history and a steadfast focus on innovation, Dr. Lal PathLabs continues to set benchmarks in the healthcare industry, solidifying its position as a trusted partner in the pursuit of optimal health outcomes.Dr. Lal Path labs Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 25,437.33 Crore | Market valuation of Dr. Lal Path labs's shares. |
| Revenue (TTM) | 2,346.44 Crore | Total revenue generated by Dr. Lal Path labs over the past twelve months. |
| Net Income (TTM) | +401.43 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | 25.32% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | 17.1% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+9.8% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+18.2% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
9.75 | Company's total debt divided by total shareholder equity. |
| Total Debt | 198.49 Crore | Sum of Dr. Lal Path labs's current & long-term financial obligations. |
| Total Cash | 1,126.7 Crore | Total amount of liquid funds available to Dr. Lal Path labs. |
| Beta | 0.29 | Beta is less than 1 indicating that the Dr. Lal Path labs's price is less volatile than the market. |
Is Dr. Lal Path labs A Good Buy For Long Term?
No valid response content found
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
